Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of
- Company
- BIO-TECHNE Corp (TECH)
- Indication
- Atopic Dermatitis
Other upcoming events for TECH
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.